|
MechanismHMG-CoA reductase inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date17 Jul 2003 |
100 Clinical Results associated with Nanjing Chenxiang Medicine Research Co Ltd
0 Patents (Medical) associated with Nanjing Chenxiang Medicine Research Co Ltd
100 Deals associated with Nanjing Chenxiang Medicine Research Co Ltd
100 Translational Medicine associated with Nanjing Chenxiang Medicine Research Co Ltd